TW201823451A - 產製視網膜色素上皮細胞之方法 - Google Patents
產製視網膜色素上皮細胞之方法 Download PDFInfo
- Publication number
- TW201823451A TW201823451A TW106131045A TW106131045A TW201823451A TW 201823451 A TW201823451 A TW 201823451A TW 106131045 A TW106131045 A TW 106131045A TW 106131045 A TW106131045 A TW 106131045A TW 201823451 A TW201823451 A TW 201823451A
- Authority
- TW
- Taiwan
- Prior art keywords
- cells
- rpe
- cultured
- days
- patent application
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 25
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 title abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 828
- 210000003583 retinal pigment epithelium Anatomy 0.000 claims description 365
- 238000000034 method Methods 0.000 claims description 116
- 239000003112 inhibitor Substances 0.000 claims description 109
- 239000012190 activator Substances 0.000 claims description 72
- 230000037361 pathway Effects 0.000 claims description 70
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 43
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 claims description 43
- CDOVNWNANFFLFJ-UHFFFAOYSA-N 4-[6-[4-(1-piperazinyl)phenyl]-3-pyrazolo[1,5-a]pyrimidinyl]quinoline Chemical compound C1CNCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C=2C3=CC=CC=C3N=CC=2)C=C1 CDOVNWNANFFLFJ-UHFFFAOYSA-N 0.000 claims description 34
- 108010082117 matrigel Proteins 0.000 claims description 31
- 108090000623 proteins and genes Proteins 0.000 claims description 22
- 108010059616 Activins Proteins 0.000 claims description 21
- 102100026818 Inhibin beta E chain Human genes 0.000 claims description 21
- 239000000488 activin Substances 0.000 claims description 21
- -1 cAMP Substances 0.000 claims description 20
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 20
- 238000012258 culturing Methods 0.000 claims description 18
- 239000000833 heterodimer Substances 0.000 claims description 17
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 238000010899 nucleation Methods 0.000 claims description 15
- 239000002356 single layer Substances 0.000 claims description 15
- 210000000130 stem cell Anatomy 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 230000003834 intracellular effect Effects 0.000 claims description 12
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 10
- 108010022355 Fibroins Proteins 0.000 claims description 10
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 claims description 10
- 102100024504 Bone morphogenetic protein 3 Human genes 0.000 claims description 9
- 101000762375 Homo sapiens Bone morphogenetic protein 3 Proteins 0.000 claims description 9
- 210000001161 mammalian embryo Anatomy 0.000 claims description 8
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims description 7
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 claims description 7
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims description 6
- 102100022545 Bone morphogenetic protein 8B Human genes 0.000 claims description 6
- 101000899390 Homo sapiens Bone morphogenetic protein 6 Proteins 0.000 claims description 6
- 101000899368 Homo sapiens Bone morphogenetic protein 8B Proteins 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 5
- JONFDFIXMPXTRH-UHFFFAOYSA-N 2-(6-methylpyridin-2-yl)-N-(pyridin-4-yl)quinazolin-4-amine Chemical compound CC1=CC=CC(C=2N=C3C=CC=CC3=C(NC=3C=CN=CC=3)N=2)=N1 JONFDFIXMPXTRH-UHFFFAOYSA-N 0.000 claims description 4
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 claims description 4
- 102100028727 Bone morphogenetic protein 15 Human genes 0.000 claims description 4
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims description 4
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 claims description 4
- 101000695367 Homo sapiens Bone morphogenetic protein 10 Proteins 0.000 claims description 4
- 101000695360 Homo sapiens Bone morphogenetic protein 15 Proteins 0.000 claims description 4
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 claims description 4
- 101000893585 Homo sapiens Growth/differentiation factor 2 Proteins 0.000 claims description 4
- IBCXZJCWDGCXQT-UHFFFAOYSA-N LY 364947 Chemical compound C=1C=NC2=CC=CC=C2C=1C1=CNN=C1C1=CC=CC=N1 IBCXZJCWDGCXQT-UHFFFAOYSA-N 0.000 claims description 4
- XHBVYDAKJHETMP-UHFFFAOYSA-N dorsomorphin Chemical class C=1C=C(C2=CN3N=CC(=C3N=C2)C=2C=CN=CC=2)C=CC=1OCCN1CCCCC1 XHBVYDAKJHETMP-UHFFFAOYSA-N 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- 230000011664 signaling Effects 0.000 claims description 4
- 150000003384 small molecules Chemical class 0.000 claims description 4
- 102100034134 Activin receptor type-1B Human genes 0.000 claims description 3
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 claims description 3
- 101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- QNZSQJBDZIOEAN-UHFFFAOYSA-N 4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol-3-yl]phenol Chemical compound CC1=CC=CC(C=2C(=C3CCCN3N=2)C=2C=CC(O)=CC=2)=N1 QNZSQJBDZIOEAN-UHFFFAOYSA-N 0.000 claims description 2
- 102100034135 Activin receptor type-1C Human genes 0.000 claims description 2
- 102100025423 Bone morphogenetic protein receptor type-1A Human genes 0.000 claims description 2
- 101000799193 Homo sapiens Activin receptor type-1C Proteins 0.000 claims description 2
- 101000934638 Homo sapiens Bone morphogenetic protein receptor type-1A Proteins 0.000 claims description 2
- WOGQPXHVUXZECW-UHFFFAOYSA-N O1COCC2=C1C=CC=C2C2=C(NC(=N2)C(C)(C)C)C2=NC(=CC=C2)C Chemical compound O1COCC2=C1C=CC=C2C2=C(NC(=N2)C(C)(C)C)C2=NC(=CC=C2)C WOGQPXHVUXZECW-UHFFFAOYSA-N 0.000 claims description 2
- 230000002457 bidirectional effect Effects 0.000 claims description 2
- 102000006533 chordin Human genes 0.000 claims description 2
- 108010008846 chordin Proteins 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 102000045246 noggin Human genes 0.000 claims description 2
- 108700007229 noggin Proteins 0.000 claims description 2
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims 8
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims 8
- 229940112869 bone morphogenetic protein Drugs 0.000 claims 8
- 108010052946 Activin Receptors Proteins 0.000 claims 3
- 102000018918 Activin Receptors Human genes 0.000 claims 3
- VRQZQTWWFHBPNK-UHFFFAOYSA-N 2-[4-methyl-2-(6-methylpyridin-2-yl)pyrazol-3-yl]thieno[3,2-c]pyridine Chemical compound C=1C2=CN=CC=C2SC=1C1=C(C)C=NN1C1=CC=CC(C)=N1 VRQZQTWWFHBPNK-UHFFFAOYSA-N 0.000 claims 1
- ROHZDDHEDXKZQL-UHFFFAOYSA-N 2-methyl-5-[6-(3-methylphenyl)-7H-imidazo[1,2-a]imidazol-5-yl]benzotriazole Chemical compound CN1N=C2C(=N1)C=CC(=C2)C2=C(N=C1N2C=CN1)C=1C=C(C=CC1)C ROHZDDHEDXKZQL-UHFFFAOYSA-N 0.000 claims 1
- HIJMSZGHKQPPJS-UHFFFAOYSA-N 3-(6-methylpyridin-2-yl)-n-phenyl-4-quinolin-4-ylpyrazole-1-carbothioamide Chemical compound CC1=CC=CC(C=2C(=CN(N=2)C(=S)NC=2C=CC=CC=2)C=2C3=CC=CC=C3N=CC=2)=N1 HIJMSZGHKQPPJS-UHFFFAOYSA-N 0.000 claims 1
- WKHRIIQNWCIMKB-UHFFFAOYSA-N 6-methyl-2-phenyl-3h-thieno[2,3-d]pyrimidin-4-one Chemical compound S1C(C)=CC(C(N2)=O)=C1N=C2C1=CC=CC=C1 WKHRIIQNWCIMKB-UHFFFAOYSA-N 0.000 claims 1
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 claims 1
- 101000899388 Homo sapiens Bone morphogenetic protein 5 Proteins 0.000 claims 1
- HFZPKQPFHTUDAU-UHFFFAOYSA-N N1(CCCCC1)CCOC1=CC=C(C=C1)C=1C=CC=2N(C=1)N=CC=2C1=CC=NC=C1 Chemical group N1(CCCCC1)CCOC1=CC=C(C=C1)C=1C=CC=2N(C=1)N=CC=2C1=CC=NC=C1 HFZPKQPFHTUDAU-UHFFFAOYSA-N 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 239000002609 medium Substances 0.000 description 85
- 230000004069 differentiation Effects 0.000 description 57
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 34
- 102100022002 CD59 glycoprotein Human genes 0.000 description 29
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 29
- 238000011081 inoculation Methods 0.000 description 29
- 239000003550 marker Substances 0.000 description 29
- 238000011529 RT qPCR Methods 0.000 description 28
- 238000003365 immunocytochemistry Methods 0.000 description 27
- 108010023082 activin A Proteins 0.000 description 26
- 101001078886 Homo sapiens Retinaldehyde-binding protein 1 Proteins 0.000 description 25
- 102100028001 Retinaldehyde-binding protein 1 Human genes 0.000 description 25
- 230000014509 gene expression Effects 0.000 description 22
- 230000033228 biological regulation Effects 0.000 description 20
- 102100035846 Pigment epithelium-derived factor Human genes 0.000 description 19
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 19
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 19
- 108090000102 pigment epithelium-derived factor Proteins 0.000 description 19
- 208000017442 Retinal disease Diseases 0.000 description 17
- 108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 description 16
- 102100030157 Microphthalmia-associated transcription factor Human genes 0.000 description 16
- 230000035755 proliferation Effects 0.000 description 16
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 15
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 15
- 230000002269 spontaneous effect Effects 0.000 description 15
- 238000002255 vaccination Methods 0.000 description 15
- 230000010261 cell growth Effects 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- 239000011435 rock Substances 0.000 description 12
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 12
- 102000007354 PAX6 Transcription Factor Human genes 0.000 description 11
- 108010032788 PAX6 Transcription Factor Proteins 0.000 description 11
- 102100022356 Tyrosine-protein kinase Mer Human genes 0.000 description 11
- 108010018804 c-Mer Tyrosine Kinase Proteins 0.000 description 11
- 238000002054 transplantation Methods 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 208000002780 macular degeneration Diseases 0.000 description 9
- 102100022794 Bestrophin-1 Human genes 0.000 description 8
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 8
- 101000903449 Homo sapiens Bestrophin-1 Proteins 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 238000012744 immunostaining Methods 0.000 description 8
- 239000002243 precursor Substances 0.000 description 8
- 238000000513 principal component analysis Methods 0.000 description 8
- 210000001525 retina Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 108010085895 Laminin Proteins 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 210000001082 somatic cell Anatomy 0.000 description 7
- 238000013518 transcription Methods 0.000 description 7
- 230000035897 transcription Effects 0.000 description 7
- 101100493820 Caenorhabditis elegans best-1 gene Proteins 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- 108010076089 accutase Proteins 0.000 description 6
- 206010064930 age-related macular degeneration Diseases 0.000 description 6
- 210000002459 blastocyst Anatomy 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 239000011247 coating layer Substances 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 206010020718 hyperplasia Diseases 0.000 description 6
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 210000000608 photoreceptor cell Anatomy 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 6
- 108010067306 Fibronectins Proteins 0.000 description 5
- 102000016359 Fibronectins Human genes 0.000 description 5
- 101150082530 TJP1 gene Proteins 0.000 description 5
- 102100034686 Tight junction protein ZO-1 Human genes 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000032459 dedifferentiation Effects 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 description 5
- 229920005575 poly(amic acid) Polymers 0.000 description 5
- 239000011148 porous material Substances 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 4
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 description 4
- 101100407335 Dictyostelium discoideum pde7 gene Proteins 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 101001020544 Homo sapiens LIM/homeobox protein Lhx2 Proteins 0.000 description 4
- 102100036132 LIM/homeobox protein Lhx2 Human genes 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 4
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 4
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 description 4
- 210000003161 choroid Anatomy 0.000 description 4
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 4
- 239000012737 fresh medium Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 101150107752 grem1 gene Proteins 0.000 description 4
- 239000000710 homodimer Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 101150087532 mitF gene Proteins 0.000 description 4
- 230000000877 morphologic effect Effects 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000004114 suspension culture Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000283074 Equus asinus Species 0.000 description 3
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 3
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 3
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 102000030621 adenylate cyclase Human genes 0.000 description 3
- 108060000200 adenylate cyclase Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 229940126513 cyclase activator Drugs 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004424 eye movement Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 229920000831 ionic polymer Polymers 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000006249 magnetic particle Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 230000003827 upregulation Effects 0.000 description 3
- PCCDKTWDGDFRME-UHFFFAOYSA-N 4-[6-(4-piperazin-1-ylphenyl)pyrazolo[1,5-a]pyrimidin-3-yl]quinoline;hydrochloride Chemical compound Cl.C1CNCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C=2C3=CC=CC=C3N=CC=2)C=C1 PCCDKTWDGDFRME-UHFFFAOYSA-N 0.000 description 2
- GJQBLGGPWGIDHB-UHFFFAOYSA-N 4-methoxy-6-[5-(6-methylpyridin-2-yl)-1h-pyrazol-4-yl]quinoline Chemical compound C1=C2C(OC)=CC=NC2=CC=C1C1=CNN=C1C1=CC=CC(C)=N1 GJQBLGGPWGIDHB-UHFFFAOYSA-N 0.000 description 2
- QJNPMPKTEIRZQN-UHFFFAOYSA-N 6-[2-(6-methylpyridin-2-yl)pyrazol-3-yl]-1h-quinazolin-4-one Chemical compound CC1=CC=CC(N2C(=CC=N2)C=2C=C3C(=O)NC=NC3=CC=2)=N1 QJNPMPKTEIRZQN-UHFFFAOYSA-N 0.000 description 2
- 108050002823 Bestrophin Proteins 0.000 description 2
- 102000012304 Bestrophin Human genes 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 101100135868 Dictyostelium discoideum pde3 gene Proteins 0.000 description 2
- 101100135859 Dictyostelium discoideum regA gene Proteins 0.000 description 2
- 101001117089 Drosophila melanogaster Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1 Proteins 0.000 description 2
- 101100407340 Drosophila melanogaster Pde8 gene Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102100030634 Homeobox protein OTX2 Human genes 0.000 description 2
- 101000584400 Homo sapiens Homeobox protein OTX2 Proteins 0.000 description 2
- 101000729271 Homo sapiens Retinoid isomerohydrolase Proteins 0.000 description 2
- 101000825086 Homo sapiens Transcription factor SOX-11 Proteins 0.000 description 2
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 101150082854 Mertk gene Proteins 0.000 description 2
- 101100407337 Mus musculus Pde8a gene Proteins 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 229940122233 Phosphodiesterase 8B inhibitor Drugs 0.000 description 2
- 229940122353 Phosphodiesterase 11 inhibitor Drugs 0.000 description 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 2
- 229940123304 Phosphodiesterase 7 inhibitor Drugs 0.000 description 2
- 101100082606 Plasmodium falciparum (isolate 3D7) PDEbeta gene Proteins 0.000 description 2
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 2
- 206010038848 Retinal detachment Diseases 0.000 description 2
- 102100031176 Retinoid isomerohydrolase Human genes 0.000 description 2
- 101100135860 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PDE2 gene Proteins 0.000 description 2
- 208000027073 Stargardt disease Diseases 0.000 description 2
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 description 2
- 102100022415 Transcription factor SOX-11 Human genes 0.000 description 2
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 210000002304 esc Anatomy 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 210000001654 germ layer Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 101150111214 lin-28 gene Proteins 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 238000004264 monolayer culture Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000008672 reprogramming Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004264 retinal detachment Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 125000003870 2-(1-piperidinyl)ethoxy group Chemical group [*]OC([H])([H])C([H])([H])N1C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- MXPZKSOVGFZLSQ-UHFFFAOYSA-N 2-(2-methylphenyl)thiophene Chemical compound CC1=CC=CC=C1C1=CC=CS1 MXPZKSOVGFZLSQ-UHFFFAOYSA-N 0.000 description 1
- DGPIDZMQLDNPGY-UHFFFAOYSA-N 2-methyl-6-(4-methyl-5-thiophen-2-ylpyrazol-1-yl)pyridine Chemical compound CC=1C=NN(C1C=1SC=CC1)C1=NC(=CC=C1)C DGPIDZMQLDNPGY-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 1
- NAMHLSFDQFXTLV-UHFFFAOYSA-N C(=S)N.CC1=CC=CC(=N1)C1=NN(C=C1C1=CC=NC2=CC=CC=C12)C1=CC=CC=C1 Chemical group C(=S)N.CC1=CC=CC(=N1)C1=NN(C=C1C1=CC=NC2=CC=CC=C12)C1=CC=CC=C1 NAMHLSFDQFXTLV-UHFFFAOYSA-N 0.000 description 1
- 101100161935 Caenorhabditis elegans act-4 gene Proteins 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 108010077078 Creatinase Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 102100038367 Gremlin-1 Human genes 0.000 description 1
- 208000007698 Gyrate Atrophy Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000773083 Homo sapiens 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 101001032872 Homo sapiens Gremlin-1 Proteins 0.000 description 1
- 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 description 1
- 101000803709 Homo sapiens Vitronectin Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 1
- 101150071986 LRAT gene Proteins 0.000 description 1
- 201000003533 Leber congenital amaurosis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 102100025744 Mothers against decapentaplegic homolog 1 Human genes 0.000 description 1
- 102100030610 Mothers against decapentaplegic homolog 5 Human genes 0.000 description 1
- 101710143113 Mothers against decapentaplegic homolog 5 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000035092 Neutral proteases Human genes 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- 102100037369 Nidogen-1 Human genes 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100025460 Protein lin-28 homolog A Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 101150116978 RPE65 gene Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000004453 Retinal Dysplasia Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 206010057430 Retinal injury Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 101700032040 SMAD1 Proteins 0.000 description 1
- 101700031501 SMAD9 Proteins 0.000 description 1
- 102000049870 Smad8 Human genes 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 102100033455 TGF-beta receptor type-2 Human genes 0.000 description 1
- 108091005735 TGF-beta receptors Proteins 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 description 1
- 108010015920 Type I Activin Receptors Proteins 0.000 description 1
- 102000002138 Type I Activin Receptors Human genes 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- YOLMUJOPRUSEGJ-QRPNPIFTSA-N [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethylimidazo[4,5-c]pyridin-7-yl]-[(3s)-3-aminopyrrolidin-1-yl]methanone;hydrochloride Chemical compound Cl.C=12N(CC)C(C=3C(=NON=3)N)=NC2=CN=CC=1C(=O)N1CC[C@H](N)C1 YOLMUJOPRUSEGJ-QRPNPIFTSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000012072 active phase Substances 0.000 description 1
- 108010023079 activin B Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 210000002987 choroid plexus Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 208000038015 macular disease Diseases 0.000 description 1
- 239000002122 magnetic nanoparticle Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 210000000472 morula Anatomy 0.000 description 1
- YOVNFNXUCOWYSG-UHFFFAOYSA-N n-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethylimidazo[4,5-c]pyridin-6-yl]oxyphenyl]-4-(2-morpholin-4-ylethoxy)benzamide Chemical compound C1=C2N(CC)C(C=3C(=NON=3)N)=NC2=CN=C1OC(C=1)=CC=CC=1NC(=O)C(C=C1)=CC=C1OCCN1CCOCC1 YOVNFNXUCOWYSG-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001020 neural plate Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 108010008217 nidogen Proteins 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 208000014380 ornithine aminotransferase deficiency Diseases 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000004243 retinal function Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 101150018078 rpe gene Proteins 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000012420 spiking experiment Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000036228 toxication Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012085 transcriptional profiling Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 description 1
- 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 210000004340 zona pellucida Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Ophthalmology & Optometry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361914445P | 2013-12-11 | 2013-12-11 | |
| US61/914,445 | 2013-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201823451A true TW201823451A (zh) | 2018-07-01 |
Family
ID=52446403
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW106131045A TW201823451A (zh) | 2013-12-11 | 2014-12-09 | 產製視網膜色素上皮細胞之方法 |
| TW103142847A TW201538726A (zh) | 2013-12-11 | 2014-12-09 | 產製視網膜色素上皮細胞之方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW103142847A TW201538726A (zh) | 2013-12-11 | 2014-12-09 | 產製視網膜色素上皮細胞之方法 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP3080248A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2017504311A (cg-RX-API-DMAC7.html) |
| KR (1) | KR101871084B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN105814194A (cg-RX-API-DMAC7.html) |
| AR (1) | AR098693A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014363032A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016012129A8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2933083A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1221734A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL245594A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2016007671A (cg-RX-API-DMAC7.html) |
| TW (2) | TW201823451A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015087231A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI855102B (zh) * | 2019-07-19 | 2024-09-11 | 日商東京威力科創股份有限公司 | 細胞的分化狀態的評價方法、自富潛能幹細胞製造視網膜色素上皮細胞的方法、胚胎幹細胞製造視網膜色素上皮細胞的方法 |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107207531B (zh) * | 2014-11-21 | 2021-05-25 | 里格尔药品股份有限公司 | 作为TGF-β抑制剂的稠合的咪唑衍生物 |
| IL273405B2 (en) * | 2014-12-30 | 2024-01-01 | Cell Cure Neurosciences Ltd | Rpe cell populations and methods of generating same |
| EP3240890B1 (en) * | 2014-12-30 | 2021-06-16 | Cell Cure Neurosciences Ltd. | Assessing retinal pigment epithelial cell populations |
| CA2972700A1 (en) * | 2014-12-30 | 2016-07-07 | Cell Cure Neurosciences Ltd. | Methods of treating retinal diseases |
| WO2017021973A1 (en) * | 2015-08-05 | 2017-02-09 | Cell Cure Neurosciences Ltd. | Preparation of retinal pigment epithelium cells |
| AU2016321170B2 (en) * | 2015-09-08 | 2022-09-01 | Fujifilm Cellular Dynamics | Method for reproducible differentiation of clinical-grade retinal pigment epithelium cells |
| CN108291206B (zh) | 2015-09-08 | 2022-07-08 | 富士胶片细胞动力公司 | 干细胞来源的视网膜色素上皮的基于macs的纯化 |
| CN108350429B (zh) | 2015-10-20 | 2022-02-25 | 富士胶片细胞动力公司 | 用于将多能干细胞定向分化为免疫细胞的方法 |
| US20180362925A1 (en) * | 2015-12-04 | 2018-12-20 | Bond University Ltd | Methods for differentiating cells |
| CN106344932B (zh) * | 2016-08-26 | 2019-12-27 | 首都医科大学附属北京同仁医院 | 一种用于提高视网膜退行性疾病基因治疗效果的组合物及其应用 |
| KR20190093199A (ko) | 2016-12-07 | 2019-08-08 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 망막 색소 상피 이식을 위해 피브린 지지체를 사용하는 방법 및 물질 |
| CN106906178A (zh) * | 2017-04-07 | 2017-06-30 | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | 培养上皮细胞的组合物及其保持上皮样细胞形态中的应用 |
| KR102668891B1 (ko) | 2017-04-18 | 2024-05-29 | 후지필름 셀룰러 다이내믹스, 인코포레이티드 | 항원-특이적 면역 이펙터 세포 |
| MX2019014503A (es) * | 2017-06-05 | 2020-01-23 | Mayo Found Medical Education & Res | Metodos y materiales para cultivar, proliferar, y diferenciar celulas madre. |
| CN109957545A (zh) | 2017-12-26 | 2019-07-02 | 江苏艾尔康生物医药科技有限公司 | 一种消化rpe细胞的方法 |
| TW202012390A (zh) * | 2018-06-29 | 2020-04-01 | 日商日本歐愛特農業科技股份有限公司 | 新穎之經取代吡唑衍生物 |
| JP2022532411A (ja) * | 2019-05-15 | 2022-07-14 | ノヴォ ノルディスク アー／エス | ヒト多能性幹細胞から眼野前駆細胞を得るための方法 |
| EP4008350A4 (en) | 2019-07-26 | 2023-06-14 | Saitama Medical University | ANTIBODY RECOGNIZING THE EXTRACELLULAR REGION OF ALK2/ACVR1 |
| CN113699097B (zh) * | 2021-09-08 | 2023-06-09 | 湖南光琇高新生命科技有限公司 | 视网膜色素上皮细胞的制备方法 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG49267A1 (en) | 1989-08-14 | 1998-05-18 | Photogenesis Inc | Surgical instrument and cell isolation and transplantation |
| US6045791A (en) | 1992-03-06 | 2000-04-04 | Photogenesis, Inc. | Retinal pigment epithelium transplantation |
| US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| US5941250A (en) | 1996-11-21 | 1999-08-24 | University Of Louisville Research Foundation Inc. | Retinal tissue implantation method |
| AU2003279132A1 (en) | 2002-10-04 | 2004-05-04 | Tissuetech, Inc. | Retinal pigment epithelial cell cultures on amniotic membrane and transplantation |
| SG10201912182UA (en) | 2004-01-23 | 2020-02-27 | Astellas Inst For Regenerative Medicine | Improved modalities for the treatment of degenerative diseases of the retina |
| CA3015835A1 (en) | 2004-11-04 | 2006-05-18 | Astellas Institute For Regenerative Medicine | Derivation of embryonic stem cells |
| US7893315B2 (en) | 2004-11-04 | 2011-02-22 | Advanced Cell Technology, Inc. | Derivation of embryonic stem cells and embryo-derived cells |
| US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
| US20090227032A1 (en) | 2005-12-13 | 2009-09-10 | Kyoto University | Nuclear reprogramming factor and induced pluripotent stem cells |
| CN101864392B (zh) | 2005-12-13 | 2016-03-23 | 国立大学法人京都大学 | 核重新编程因子 |
| JP5441099B2 (ja) | 2007-01-18 | 2014-03-12 | 独立行政法人理化学研究所 | 視細胞への分化誘導方法 |
| CA2684242C (en) | 2007-03-23 | 2019-11-12 | Wisconsin Alumni Research Foundation | Somatic cell reprogramming |
| JP5395058B2 (ja) * | 2007-04-18 | 2014-01-22 | ハダシット メディカル リサーチ サーヴィシーズ アンド ディヴェロップメント リミテッド | 幹細胞に由来する網膜色素上皮細胞 |
| JP2008307007A (ja) | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
| CA3177952A1 (en) | 2007-10-12 | 2009-04-23 | Astellas Institute For Regenerative Medicine | Improved methods of producing rpe cells and compositions of rpe cells |
| GB0806746D0 (en) | 2008-04-14 | 2008-05-14 | Ucl Business Plc | Membrane |
| CA3066806C (en) | 2009-08-24 | 2023-03-07 | David M. Gamm | Substantially pure human retinal progenitor, forebrain progenitor, and retinal pigment epithelium cell cultures and methods of making the same |
| WO2011063005A2 (en) | 2009-11-17 | 2011-05-26 | Advanced Cell Technology, Inc. | Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells |
| ES2542226T3 (es) | 2010-04-28 | 2015-08-03 | Technische Universität Dresden | Método para producir células progenitoras retinianas polarizadas a partir de células madre pluripotentes y su diferenciación para dar células del epitelio pigmentario retiniano |
| EP3578988B1 (en) * | 2010-05-25 | 2025-01-22 | Memorial Sloan-Kettering Cancer Center | Method of nociceptor differentiantion of human embryonic stem cells and uses thereof |
| GB201011313D0 (en) | 2010-07-05 | 2010-08-18 | Ucl Business Plc | Implantation devices, methods and implants |
| EP3549617B1 (en) | 2010-07-12 | 2023-09-13 | University of Southern California | Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same |
| US8871744B2 (en) | 2010-07-21 | 2014-10-28 | B & G Partyers, LLC | Compounds and methods for selectively targeting tumor-associated mucins |
| CN102465111A (zh) * | 2010-11-19 | 2012-05-23 | 薛志刚 | 一种体外人胚胎干细胞诱导分化为视网膜色素上皮细胞的试验方法 |
| RU2590864C2 (ru) | 2011-01-18 | 2016-07-10 | МИНИПАМПЗ, ЭлЭлСи | Хирургический инструмент для имплантации |
| WO2012177968A1 (en) | 2011-06-22 | 2012-12-27 | The Schepens Eye Research Institute, Inc. | A scaffold for subretinal cell transplantation and drug delivery |
| HUE044778T2 (hu) | 2011-11-14 | 2019-11-28 | Astellas Inst For Regenerative Medicine | Humán RPE sejt gyógyászati készítmények és alkalmazásaik |
| US9850463B2 (en) | 2012-02-01 | 2017-12-26 | The Regents Of The University Of California | Methods of culturing retinal pigmented epithelium cells, including xeno-free production, RPE enrichment, and cryopreservation |
| CN102618488A (zh) * | 2012-03-15 | 2012-08-01 | 中国人民解放军第三军医大学第一附属医院 | 一种制备视网膜色素上皮细胞的方法 |
| ES2688019T3 (es) | 2012-06-05 | 2018-10-30 | The Regents Of The University Of California | Métodos y composiciones para la producción acelerada de células epiteliales pigmentadas retinianas a partir de células pluripotentes |
| AU2014212230B2 (en) | 2013-02-01 | 2019-07-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method for generating retinal pigment epithelium (RPE) cells from induced pluripotent stem cells (iPSCs) |
-
2014
- 2014-12-08 WO PCT/IB2014/066703 patent/WO2015087231A1/en not_active Ceased
- 2014-12-08 KR KR1020167018138A patent/KR101871084B1/ko not_active Expired - Fee Related
- 2014-12-08 CN CN201480067617.3A patent/CN105814194A/zh active Pending
- 2014-12-08 EP EP14833537.5A patent/EP3080248A1/en not_active Withdrawn
- 2014-12-08 HK HK16109751.2A patent/HK1221734A1/zh unknown
- 2014-12-08 CA CA2933083A patent/CA2933083A1/en not_active Abandoned
- 2014-12-08 BR BR112016012129A patent/BR112016012129A8/pt not_active Application Discontinuation
- 2014-12-08 JP JP2016538000A patent/JP2017504311A/ja active Pending
- 2014-12-08 AU AU2014363032A patent/AU2014363032A1/en not_active Abandoned
- 2014-12-08 MX MX2016007671A patent/MX2016007671A/es unknown
- 2014-12-09 TW TW106131045A patent/TW201823451A/zh unknown
- 2014-12-09 TW TW103142847A patent/TW201538726A/zh unknown
- 2014-12-10 AR ARP140104590A patent/AR098693A1/es unknown
-
2016
- 2016-05-10 IL IL245594A patent/IL245594A0/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI855102B (zh) * | 2019-07-19 | 2024-09-11 | 日商東京威力科創股份有限公司 | 細胞的分化狀態的評價方法、自富潛能幹細胞製造視網膜色素上皮細胞的方法、胚胎幹細胞製造視網膜色素上皮細胞的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015087231A1 (en) | 2015-06-18 |
| JP2017504311A (ja) | 2017-02-09 |
| CA2933083A1 (en) | 2015-06-18 |
| CN105814194A (zh) | 2016-07-27 |
| BR112016012129A2 (pt) | 2017-08-08 |
| AU2014363032A1 (en) | 2016-06-09 |
| MX2016007671A (es) | 2016-10-14 |
| BR112016012129A8 (pt) | 2020-05-12 |
| IL245594A0 (en) | 2016-06-30 |
| KR20160095118A (ko) | 2016-08-10 |
| EP3080248A1 (en) | 2016-10-19 |
| KR101871084B1 (ko) | 2018-06-25 |
| TW201538726A (zh) | 2015-10-16 |
| AR098693A1 (es) | 2016-06-08 |
| HK1221734A1 (zh) | 2017-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201823451A (zh) | 產製視網膜色素上皮細胞之方法 | |
| US20150159134A1 (en) | Method for producing retinal pigment epithelial cells | |
| JP5721111B2 (ja) | 幹細胞の培地及び培養方法 | |
| AU2014352773B2 (en) | Specification of functional cranial placode derivatives from human pluripotent stem cells | |
| US20190249140A1 (en) | Methods for neural conversion of human embryonic stem cells | |
| JP7029144B2 (ja) | 腺性下垂体又はその前駆組織の製造方法 | |
| JP5843775B2 (ja) | 幹細胞を分化させるための重量オスモル濃度の操作法 | |
| WO2017183732A1 (ja) | 網膜組織の製造法 | |
| KR102297580B1 (ko) | 전안부 조직의 제조 방법 | |
| CN112204134A (zh) | 眼细胞的分化方法及其用途 | |
| AU2017214749B2 (en) | Methods of differentiating stem cell-derived ectodermal lineage precursors | |
| CN107109361A (zh) | 制备小脑祖先组织的方法 | |
| JP7766724B2 (ja) | オリゴデンドロサイト前駆細胞組成物 | |
| Saito‐Diaz et al. | Autonomic neurons with sympathetic character derived from human pluripotent stem cells | |
| KR20070029745A (ko) | 배아 줄기 세포의 영양 세포 독립적 장기간 배양 | |
| JP7737672B2 (ja) | 下垂体ホルモン産生細胞及びその前駆細胞の分離法 | |
| KR20240093530A (ko) | 뇌하수체 호르몬 생산 세포를 포함하는 세포 응집체 및 그 생산 방법 | |
| WO2023054325A1 (ja) | 細胞表面マーカーを用いた下垂体細胞および視床下部細胞の分離法 | |
| WO2024182860A1 (en) | Methods and compositions for in vitro haematopoiesis and lymphopoiesis | |
| HK40086565A (en) | Method for separating pituitary hormone-producing cells and progenitor cells thereof |